ICON PLC
Close on Oct 19, 2026
- Market cap
- $13.01B
- P/E (TTM)
- 300.2
- Dividend yield
- –
About ICON
Services-Commercial Physical & Biological Research, SIC 8731
ICON public limited company is a contract research organization that provides outsourced development, commercialization, and consulting services to the pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company supports all phases of the clinical development process, from compound selection through Phase I to IV clinical studies, post-approval research, and market access. Its core service offerings encompass clinical development, functional service partnerships, decentralized clinical trial solutions, and specialized laboratory testing, including bio-analytical, biomarker, vaccine, and central laboratory services.
The company operates globally with approximately 40,100 employees across 97 locations in 55 countries. Its dedicated site network includes 21 owned or embedded clinical sites across the United States, the United Kingdom, and Spain. ICON maintains its principal executive office and corporate headquarters in Dublin, Ireland.
Summary of the business section of ICON's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ICON PLC
- Founded
- 1990
- Headquarters
- Dublin 18, L2
- Address
- South County Business Park, Leopardstown 00000
- Phone
- 00 353 1 291 2000
- Website
- iconplc.com
- Employees
- 40,100, Dec 31, 2025
- Industry
- Services-Commercial Physical & Biological Research
- Auditor
- Ernst & Young Chartered Accountants, Dublin, Ireland
Stock & identifiers
- Ticker
- ICLR
- Exchange
- Nasdaq
- IPO date
- Aug 7, 2003
- Shares outstanding
- 77M, Dec 31, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Aug 13, 2008; 2-for-1, Oct 24, 2006
- SEC CIK
- 1060955
- CUSIP
- G4705A100
- ISIN
- USG4705A1000
- EIN
- 98-1067160
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Barry Edward Balfe | Chief Executive Officer, Director | 4,804 |
| Nigel Bernard John Clerkin | Chief Financial Officer | 7,652 |
| Emer Lyons | Chief Accounting Officer | 752 |
| John Dr Climax | Director | 293,553 |
| Eugene Pacelli McCague | Director | 3,811 |
| Ronan Martin Murphy | Director | 8,852 |
| Linda Grais | Director | 6,819 |
| Ciaran Murray | Director | 22,849 |
| Kevin Francis Egan | Director | – |
| Anne Clem Whitaker | Director | 958 |
| Julie O'Neill | Director | 3,588 |
| Jeffrey Thomas Elliott | Director | – |
| Stephen A. Cutler | Director | 79,278 |
Employees
Headcount reported in annual reports
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 1, 2026 | Late filing | Notification of late filing |
| Mar 31, 2021 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Aug 7, 2003 | IPO | Initial public offering priced (424B4 prospectus) |